JP2005521389A - T細胞受容体様特異性を有し、さらに高親和性の抗体ならびに癌、ウイルス感染、および自己免疫疾患の検出および治療でのその使用 - Google Patents
T細胞受容体様特異性を有し、さらに高親和性の抗体ならびに癌、ウイルス感染、および自己免疫疾患の検出および治療でのその使用 Download PDFInfo
- Publication number
- JP2005521389A JP2005521389A JP2003567383A JP2003567383A JP2005521389A JP 2005521389 A JP2005521389 A JP 2005521389A JP 2003567383 A JP2003567383 A JP 2003567383A JP 2003567383 A JP2003567383 A JP 2003567383A JP 2005521389 A JP2005521389 A JP 2005521389A
- Authority
- JP
- Japan
- Prior art keywords
- hla
- restricted antigen
- moiety
- mhc
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims description 60
- 201000011510 cancer Diseases 0.000 title claims description 28
- 208000036142 Viral infection Diseases 0.000 title claims description 13
- 230000009385 viral infection Effects 0.000 title claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 title claims description 11
- 238000011282 treatment Methods 0.000 title claims description 6
- 210000001744 T-lymphocyte Anatomy 0.000 title description 21
- 238000001514 detection method Methods 0.000 title description 3
- 108091007433 antigens Proteins 0.000 claims abstract description 151
- 102000036639 antigens Human genes 0.000 claims abstract description 151
- 239000000427 antigen Substances 0.000 claims abstract description 150
- 230000027455 binding Effects 0.000 claims abstract description 143
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims abstract description 126
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims abstract description 126
- 230000001225 therapeutic effect Effects 0.000 claims abstract description 37
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 139
- 210000004027 cell Anatomy 0.000 claims description 90
- 238000000034 method Methods 0.000 claims description 74
- 108010074032 HLA-A2 Antigen Proteins 0.000 claims description 70
- 102000025850 HLA-A2 Antigen Human genes 0.000 claims description 68
- 108091033319 polynucleotide Proteins 0.000 claims description 53
- 102000040430 polynucleotide Human genes 0.000 claims description 53
- 239000002157 polynucleotide Substances 0.000 claims description 53
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 52
- 108090000623 proteins and genes Proteins 0.000 claims description 46
- 108091054437 MHC class I family Proteins 0.000 claims description 39
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 33
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 102000043129 MHC class I family Human genes 0.000 claims description 26
- 230000001363 autoimmune Effects 0.000 claims description 22
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 20
- 230000003612 virological effect Effects 0.000 claims description 20
- 230000001472 cytotoxic effect Effects 0.000 claims description 19
- 238000004519 manufacturing process Methods 0.000 claims description 19
- 229940051026 immunotoxin Drugs 0.000 claims description 18
- 239000002596 immunotoxin Substances 0.000 claims description 18
- -1 HLA-A34 Proteins 0.000 claims description 17
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 16
- 230000002637 immunotoxin Effects 0.000 claims description 14
- 231100000608 immunotoxin Toxicity 0.000 claims description 14
- 238000002823 phage display Methods 0.000 claims description 14
- 108010026122 HLA-A*33 antigen Proteins 0.000 claims description 13
- 108010035452 HLA-A1 Antigen Proteins 0.000 claims description 13
- 108010013476 HLA-A24 Antigen Proteins 0.000 claims description 13
- 108010029526 HLA-A28 antigen Proteins 0.000 claims description 13
- 108010086377 HLA-A3 Antigen Proteins 0.000 claims description 13
- 108010018475 HLA-A31 antigen Proteins 0.000 claims description 13
- 108010091938 HLA-B7 Antigen Proteins 0.000 claims description 13
- 108010028938 HLA-B45 antigen Proteins 0.000 claims description 12
- 231100000433 cytotoxic Toxicity 0.000 claims description 12
- 230000003053 immunization Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102000004127 Cytokines Human genes 0.000 claims description 9
- 108090000695 Cytokines Proteins 0.000 claims description 9
- 108020004999 messenger RNA Proteins 0.000 claims description 9
- 241000700605 Viruses Species 0.000 claims description 8
- 231100000331 toxic Toxicity 0.000 claims description 8
- 230000002588 toxic effect Effects 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 7
- 230000003993 interaction Effects 0.000 claims description 7
- 150000007523 nucleic acids Chemical class 0.000 claims description 7
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 239000003053 toxin Substances 0.000 claims description 6
- 231100000765 toxin Toxicity 0.000 claims description 6
- 108700012359 toxins Proteins 0.000 claims description 6
- 102000034287 fluorescent proteins Human genes 0.000 claims description 5
- 108091006047 fluorescent proteins Proteins 0.000 claims description 5
- 210000000628 antibody-producing cell Anatomy 0.000 claims description 4
- 101000937544 Homo sapiens Beta-2-microglobulin Proteins 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 102000047279 human B2M Human genes 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 230000008569 process Effects 0.000 claims description 3
- 238000012544 monitoring process Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 150000001413 amino acids Chemical group 0.000 description 32
- 239000012634 fragment Substances 0.000 description 25
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 21
- 101000691214 Haloarcula marismortui (strain ATCC 43049 / DSM 3752 / JCM 8966 / VKM B-1809) 50S ribosomal protein L44e Proteins 0.000 description 20
- 108091008874 T cell receptors Proteins 0.000 description 19
- 241000699670 Mus sp. Species 0.000 description 14
- 230000004048 modification Effects 0.000 description 13
- 238000012986 modification Methods 0.000 description 13
- 238000002965 ELISA Methods 0.000 description 12
- 241000588724 Escherichia coli Species 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 11
- 238000004091 panning Methods 0.000 description 11
- 238000013459 approach Methods 0.000 description 10
- 230000021615 conjugation Effects 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 238000004458 analytical method Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 238000002649 immunization Methods 0.000 description 8
- 210000003000 inclusion body Anatomy 0.000 description 8
- 201000001441 melanoma Diseases 0.000 description 8
- 125000000539 amino acid group Chemical group 0.000 description 7
- 150000001718 carbodiimides Chemical class 0.000 description 7
- 238000009169 immunotherapy Methods 0.000 description 7
- 238000010348 incorporation Methods 0.000 description 7
- 230000008685 targeting Effects 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 239000013598 vector Substances 0.000 description 7
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 108700033844 Pseudomonas aeruginosa toxA Proteins 0.000 description 6
- 230000030741 antigen processing and presentation Effects 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 238000005516 engineering process Methods 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 238000011830 transgenic mouse model Methods 0.000 description 6
- 230000014616 translation Effects 0.000 description 6
- JWDFQMWEFLOOED-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(pyridin-2-yldisulfanyl)propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSC1=CC=CC=N1 JWDFQMWEFLOOED-UHFFFAOYSA-N 0.000 description 5
- 108010037618 HLA-C*08 antigen Proteins 0.000 description 5
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 5
- 102100034256 Mucin-1 Human genes 0.000 description 5
- 102000057297 Pepsin A Human genes 0.000 description 5
- 108090000284 Pepsin A Proteins 0.000 description 5
- 108010090804 Streptavidin Proteins 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229960002685 biotin Drugs 0.000 description 5
- 239000011616 biotin Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 102000054766 genetic haplotypes Human genes 0.000 description 5
- 230000002163 immunogen Effects 0.000 description 5
- 230000000670 limiting effect Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 5
- 230000007017 scission Effects 0.000 description 5
- 230000009261 transgenic effect Effects 0.000 description 5
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 108010093488 His-His-His-His-His-His Proteins 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 4
- SNDPXSYFESPGGJ-UHFFFAOYSA-N L-norVal-OH Natural products CCCC(N)C(O)=O SNDPXSYFESPGGJ-UHFFFAOYSA-N 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 125000003118 aryl group Chemical group 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 229940111202 pepsin Drugs 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000009870 specific binding Effects 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- 230000005730 ADP ribosylation Effects 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 238000012286 ELISA Assay Methods 0.000 description 3
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- 108010017842 Telomerase Proteins 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 3
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000007363 ring formation reaction Methods 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 230000005945 translocation Effects 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 2
- OYIFNHCXNCRBQI-UHFFFAOYSA-N 2-aminoadipic acid Chemical compound OC(=O)C(N)CCCC(O)=O OYIFNHCXNCRBQI-UHFFFAOYSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 2
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- SNDPXSYFESPGGJ-BYPYZUCNSA-N L-2-aminopentanoic acid Chemical compound CCC[C@H](N)C(O)=O SNDPXSYFESPGGJ-BYPYZUCNSA-N 0.000 description 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 2
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 2
- 108090000526 Papain Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 108010092262 T-Cell Antigen Receptors Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000007413 biotinylation Methods 0.000 description 2
- 230000006287 biotinylation Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000012875 competitive assay Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001268 conjugating effect Effects 0.000 description 2
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 2
- 238000004255 ion exchange chromatography Methods 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 108700043516 mouse H-2Kb Proteins 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 229960003104 ornithine Drugs 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 238000000159 protein binding assay Methods 0.000 description 2
- 229940051173 recombinant immunotoxin Drugs 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 230000006641 stabilisation Effects 0.000 description 2
- 238000011105 stabilization Methods 0.000 description 2
- 108010044720 telomerase reverse transcriptase (540-548) Proteins 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- KYRUKRFVOACELK-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-(4-hydroxyphenyl)propanoate Chemical compound C1=CC(O)=CC=C1CCC(=O)ON1C(=O)CCC1=O KYRUKRFVOACELK-UHFFFAOYSA-N 0.000 description 1
- FYMNTAQFDTZISY-QMMMGPOBSA-N (2s)-2-amino-3-[4-(diaminomethylideneamino)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N=C(N)N)C=C1 FYMNTAQFDTZISY-QMMMGPOBSA-N 0.000 description 1
- RUFPHBVGCFYCNW-UHFFFAOYSA-N 1-naphthylamine Chemical compound C1=CC=C2C(N)=CC=CC2=C1 RUFPHBVGCFYCNW-UHFFFAOYSA-N 0.000 description 1
- BLCJBICVQSYOIF-UHFFFAOYSA-N 2,2-diaminobutanoic acid Chemical compound CCC(N)(N)C(O)=O BLCJBICVQSYOIF-UHFFFAOYSA-N 0.000 description 1
- SKWCZPYWFRTSDD-UHFFFAOYSA-N 2,3-bis(azaniumyl)propanoate;chloride Chemical compound Cl.NCC(N)C(O)=O SKWCZPYWFRTSDD-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102100030343 Antigen peptide transporter 2 Human genes 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091035707 Consensus sequence Proteins 0.000 description 1
- 208000017815 Dendritic cell tumor Diseases 0.000 description 1
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-N Formic acid Chemical compound OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101100268553 Homo sapiens APP gene Proteins 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- 102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
- 108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 101100045406 Mus musculus Tap2 gene Proteins 0.000 description 1
- PQNASZJZHFPQLE-UHFFFAOYSA-N N(6)-methyllysine Chemical compound CNCCCCC(N)C(O)=O PQNASZJZHFPQLE-UHFFFAOYSA-N 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010034016 Paronychia Diseases 0.000 description 1
- 108010043958 Peptoids Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 101800000849 Tachykinin-associated peptide 2 Proteins 0.000 description 1
- 101000980463 Treponema pallidum (strain Nichols) Chaperonin GroEL Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 102000025171 antigen binding proteins Human genes 0.000 description 1
- 108091000831 antigen binding proteins Proteins 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 210000001106 artificial yeast chromosome Anatomy 0.000 description 1
- 230000006470 autoimmune attack Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000006664 bond formation reaction Methods 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 125000001589 carboacyl group Chemical group 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000003198 gene knock in Methods 0.000 description 1
- 238000003209 gene knockout Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000013595 glycosylation Effects 0.000 description 1
- 238000006206 glycosylation reaction Methods 0.000 description 1
- 102000007192 gp100 Melanoma Antigen Human genes 0.000 description 1
- 108010008486 gp100 Melanoma Antigen Proteins 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000008004 immune attack Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 229940127121 immunoconjugate Drugs 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000010189 intracellular transport Effects 0.000 description 1
- RGXCTRIQQODGIZ-UHFFFAOYSA-O isodesmosine Chemical compound OC(=O)C(N)CCCC[N+]1=CC(CCC(N)C(O)=O)=CC(CCC(N)C(O)=O)=C1CCCC(N)C(O)=O RGXCTRIQQODGIZ-UHFFFAOYSA-O 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 108010003486 leucyl-leucyl-phenylalanyl-glycyl-tyrosyl-prolyl-valyl-tyrosyl-valine Proteins 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229940023041 peptide vaccine Drugs 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- USRGIUJOYOXOQJ-GBXIJSLDSA-N phosphothreonine Chemical compound OP(=O)(O)O[C@H](C)[C@H](N)C(O)=O USRGIUJOYOXOQJ-GBXIJSLDSA-N 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 239000000700 radioactive tracer Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 125000006850 spacer group Chemical group 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000007474 system interaction Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960001005 tuberculin Drugs 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Description
本発明を、本明細書中で、例示のみを目的として添付の図面を参照して記載する。ここでは詳細な図面を参照して、示した個々の事項は本発明の好ましい実施形態の例示および例示的考察のみを目的とし、最も有用と考えられるものを示すことおよび本発明の原理および概念的局面の説明が容易に理解されるために示すことを強調する。これに関して、本発明の基本的理解に必要とされる以上により詳細に本発明の構造細部を示すことを意図せず、図面と共に示した説明により、どのようにして本発明のいくつかの形態を実際に実施することができるのかが当業者に明らかとなる。
図面において、
図1A−Bは組換えscHLA−A2−ペプチド複合体に対するポリクローナルファージELISAを示す棒グラフを示す。プレートに、以下の実施例に記載の表示のscMHC−ペプチド複合体でコートする。最初のライブラリーのポリクローナルファージ集団(L)または各パニングラウンド後に溶出したファージ(I−IV)の結合を示す。図1A−pCANTAB scFvライブラリー由来のファージ;図1B−scFv−CBDライブラリー由来のファージ。ビオチン化scMHC−ペプチド複合体を使用したELISAによって結合特異性研究を行った。ELISAプレート(Falcon)に、BSA−ビオチン(1μg/ウェル)で一晩コートし、洗浄し、ストレプトアビジン(1μg/ウェル)とインキュベートし(室温で1時間)、再度十分に洗浄し、0.5μgのMHC/ペプチド複合体とさらにインキュベートした(室温で1時間)。プレートをPBS/2%ミルクでブロックし(室温で30分間)、ファージクローン(約109以下のファージ/ウェル、室温で1時間)または0.5〜1μgの可溶性scFvまたはscFv−PE38とインキュベートし、その後1000倍希釈のHRP抱合/抗M13、抗myc抗体、または抗PE抗体でそれぞれ洗浄した。特異性研究のために使用したHLA−A2拘束性ペプチドは、gp100(154):KTWGQYWQV(配列番号1);gp100(209):IMDQVPFSV(配列番号2);gp100(280):YLEPGPVTV(配列番号3);MUC1:LLLTVLTVL(配列番号4);HTLV−1(TAX):LLFGYPVYV(配列番号5);hTERT(540):ILAKFLHWL(配列番号6);hTERT(865):RLVDDFLLV(配列番号7)である。
図2A−BはscHLA−A2/gp100複合体へのモノクローナルファージクローンの異なる結合を示す棒グラフを示す。gp100由来エピトープと複合体形成した固定化scHLA−A2への結合についてモノクローナルファージを試験した。図2A−G9−209M;図2B−G9−280V。上記図1に記載のようにアッセイを行った。
図3Aは抗体G1scFvの核酸配列(配列番号8)およびアミノ酸配列(配列番号9)を示す。CDRを太字で示し、VHおよびVLドメインに連結したペプチドリンカーに下線を引いている。
図3B−Cは精製G1scFvおよびG1scFv−PE38のSDS−PAGEを示す。G1 scFv遺伝子を、PCRによってファージクローンからレスキューし、SfiI−NotIクローニング部位を介してファージミドベクターpCANTAB6にサブクローニングした。Mycおよびヘキサヒスチジンタグを、scFv遺伝子のC末端に融合した。以前に記載のように(29)BL21 λDE3細胞中でscFv抗体を発現させ、金属イオンアフィニティクロマトグラフィによってペリプラズム画分から精製した。G1scFv−PE38融合タンパク質の発現のために、scFv遺伝子をNcoI−NotIフラグメントとしてPEの転位およびADP−リボシル化ドメイン(PE38)をコードするプラスミドpIB−NNにサブクローニングした。BL21 λDE3細胞での発現、封入体からの再折りたたみ、およびG1scFv−PE38の精製を、以前に記載のように行った(30)。
図4はG1 scFv−PE38の結合特異性を示す棒グラフである。免疫プレートに、記載のように種々の表示のscHLA−A2−ペプチド複合体でコートし、固定化複合体へのG1 scFv−PE38の結合を、抗PE抗体を使用して検出した。
図5A−BはTCR様G1 scFvの結合特性を証明するプロットを示す。5A−精製された可溶性G1 scFvの滴定ELISA。ウェルに以下のl実施例に記載のMHC−ペプチド複合体をコートした。5B−精製されたG1 scFv−PE38のHLA−A2/G9−209M複合体への125I標識G1 scFv−PE38の結合を阻害する能力の競合結合分析。組換えscFvの見かけ上の結合親和性を、125I標識トレーサーの結合の50%阻害に必要な競合物質(可溶性精製G1scFv−PE38)の濃度として決定した。可撓性ELISAプレートにBSA−ビオチンをコートし、scMHC−ペプチド複合体(100μl中10μg)を以前に記載のように固定した。組換えG1scFv−PE38を、Bolton−Hunter試薬を使用して[125I]で標識した。標識タンパク質を、競合物質として漸増濃度の冷G1scFv−PE38の存在下でトレーサーとしてウェルに添加し(3〜5×105CPM/ウェル)、PBS中にて室温で1時間インキュベートした。プレートをPBSで完全に洗浄し、結合放射能をγカウンターで決定した。G1scFv−PE38の見かけ上の親和性を、固定scMHC−ペプチド複合体への[125I]標識G1scFv−PE38結合の50%阻害の達成に必要な競合物質濃度の推定によって決定した。非特異的結合を、20〜40倍過剰の非標識Fabの添加によって決定した。
図6A−CはG1 scFvのAPCへの結合を証明するプロットを示す。RMAS−HHDまたはJY細胞を、表示のHLA−2A拘束性ペプチドと共に負荷した。次いで、ペプチド負荷細胞を、可溶性精製G1scFv抗体とインキュベートした。FITC標識抗Mycを使用して結合を検出した。PMAS−HHD細胞をG9−209およびG9−280ペプチドと共に負荷し、コントロール非負荷細胞である抗HLA抗体w6/32(6A)または抗HLA−A2抗体BB7.2(6B)と共に染色して、負荷したペプチド表面でHLA−A2複合体の安定化/発現が証明されたが、ペプチド非負荷細胞では証明されなかった。G9−209またはG9−208ペプチド負荷細胞をG1 scFvで染色し、分染を示す(6C)。単鎖β2M−HLA−A2遺伝子(26)またはEBV形質転換Bリンパ芽球JY細胞(106細胞)でトランスフェクトしたB細胞株RMAS−HHDを無血清RPMIで2回洗浄し、100μMのペプチドを含む培地中にて26℃または37℃でそれぞれ一晩インキュベートした。その後、APCを37℃で2〜3時間インキュベートしてMHC−ペプチド複合体の細胞表面発現を安定化し、その後100μlの組換えscFv(10〜50μg/ml、60〜90分間、4℃)とインキュベートした。次いで、細胞を洗浄し、FITC標識抗Myc抗体とインキュベートし(30〜45分間、4℃)、最後に洗浄してFACStarフローサイトメーター(Becton Dickinson)で分析した。黒色腫細胞に、37℃で1〜10μMのペプチドをパルスし、本明細書中に記載のようにscFvで染色した。
図7A−Cはペプチド負荷APCに対するG1 scFv−PE38の細胞傷害活性を証明するプロットおよび棒グラフである。RMAS−HHD(7A)またはJY(7B)細胞を、表示のHLA−A2拘束性ペプチドと共に負荷し、その後漸増濃度のG1 scFvーPE38とインキュベートした。細胞タンパク質への3H−ロイシン取り込みによってタンパク質合成を決定した。(7C)では、過剰(0.15〜0.25mg/ml)の表示のscHLA−A2−ペプチド複合体をウェルに添加し、その後G1 scFv−PE38(25〜50ng/ml)を添加した。上記のように、RMAS−HHDおよびJY APCをG9−209ペプチドおよびコントロールペプチドと共に負荷した。その後、ペプチド負荷細胞を漸増濃度のG1scFv−PE38とインキュベートし、以前に記載のように(30)細胞タンパク質の3H−ロイシン取り込みの測定によってタンパク質合成阻害を決定した。タンパク質合成の50%阻害に必要なG1scFv−PE38濃度としてIC50を決定した。競合アッセイでは、過剰の特異的および非特異的HLA−A2−ペプチド複合体(35〜50μg/ウェル)を15分間ウェルに添加し、その後G1scFv−PE38を添加した。
P1−P2−P3−P4−P5−P6−P7−P8−P9。
(式中、Rは、例えば、任意の1つまたは複数のn炭素に存在するメチル、エチル、またはプロピルである)などが含まれるが、これらに限定されない)に置換することもできる。
ここでは、上記説明と共に以下の実施例を参照して、非限定的様式で本発明を例示する。
配列番号2はHLA−A2拘束性ペプチドgp100(209)の配列である。
配列番号3はHLA−A2拘束性ペプチドgp100(280)の配列である。
配列番号4はHLA−A2拘束性ペプチドMUC1の配列である。
配列番号5はHLA−A2拘束性ペプチドHTLV−1(TAX)の配列である。
配列番号6はHLA−A2拘束性ペプチドhTEroom temperature(540)の配列である。
配列番号7はHLA−A2拘束性ペプチドhTEroom temperature(865)の配列である。
配列番号8はG1一本鎖Fv組換え抗体DNAの配列である。
配列番号9はG1一本鎖Fv組換え抗体タンパク質の配列である。
配列番号10はインフルエンザ由来のHLA拘束性ペプチドの配列である。
配列番号11はB型肝炎由来のHLA拘束性ペプチドの配列である。
Claims (64)
- HLA拘束性抗原と複合体形成したヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む単離分子。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項1記載の単離分子。
- 前記抗体に抱合する同定可能な部分をさらに含む請求項1記載の単離分子。
- 前記同定可能部分は、結合対のメンバーおよび標識からなる群から選択される請求項3記載の単離分子。
- 前記結合対の前記メンバーが抗原である請求項3記載の単離分子。
- 前記標識は、蛍光タンパク質および酵素からなる群から選択される請求項3記載の単離分子。
- 前記抗体に抱合する治療部分をさらに含む請求項1記載の単離分子。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項7記載の単離分子。
- 前記HLA拘束性抗原が腫瘍HLA拘束性抗原である請求項1記載の単離分子。
- 前記HLA拘束性抗原がウイルスHLA拘束性抗原である請求項1記載の単離分子。
- 前記HLA拘束性抗原が自己免疫HLA拘束性抗原である請求項1記載の単離分子。
- HLA拘束性抗原と複合体形成したヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む治療有効量の分子を含む薬学的組成物であって、前記分子は前記抗体に抱合する治療部分をさらに含む薬学的組成物。
- 薬学的に許容可能なキャリアをさらに含む請求項12記載の薬学的組成物。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項12記載の薬学的組成物。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項12記載の薬学的組成物。
- 前記HLA拘束性抗原が腫瘍HLA拘束性抗原である請求項12記載の薬学的組成物。
- 前記HLA拘束性抗原がウイルスHLA拘束性抗原である請求項12記載の薬学的組成物。
- 前記HLA拘束性抗原が自己免疫HLA拘束性抗原である請求項12記載の薬学的組成物。
- HLA拘束性抗原と複合体形成したヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む分子を含む診断組成物であって、前記分子は前記抗体に抱合した同定可能部分をさらに含む診断組成物。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項19記載の診断組成物。
- 前記同定可能部分は、結合対のメンバーおよび標識からなる群から選択される請求項19記載の診断組成物。
- 前記結合対の前記メンバーが抗原である請求項19記載の診断組成物。
- 前記標識は、蛍光タンパク質および酵素からなる群から選択される請求項19記載の診断組成物。
- 前記HLA拘束性抗原が腫瘍HLA拘束性抗原である請求項19記載の診断組成物。
- 前記HLA拘束性抗原がウイルスHLA拘束性抗原である請求項19記載の診断組成物。
- 前記HLA拘束性抗原が自己免疫HLA拘束性抗原である請求項19記載の診断組成物。
- HLA拘束性抗原と複合体形成したヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体をコードする第1のポリヌクレオチドを含む単離分子。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項27記載の単離分子。
- 前記第1のポリヌクレオチドに連結し、同定可能部分をコードする第2のポリヌクレオチドをさらに含む請求項27記載の単離分子。
- 前記同定可能部分は、結合対のメンバーおよび標識からなる群から選択される請求項29記載の単離分子。
- 前記結合対の前記メンバーが抗原である請求項29記載の単離分子。
- 前記標識は、蛍光タンパク質および酵素からなる群から選択される請求項29記載の単離分子。
- 前記第1のポリヌクレオチドに連結し、治療部分をコードする第2のポリヌクレオチドをさらに含む請求項27記載の単離分子。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項33記載の単離分子。
- 前記HLA拘束性抗原が腫瘍HLA拘束性抗原である請求項27記載の単離分子。
- 前記HLA拘束性抗原がウイルスHLA拘束性抗原である請求項27記載の単離分子。
- 前記HLA拘束性抗原が自己免疫HLA拘束性抗原である請求項27記載の単離分子。
- 以下の工程を含む、HLA拘束性抗原と複合体形成したヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体の産生方法:
前記ヒト主要組織適合性複合体(MHC)クラスIを発現する細胞を有する遺伝子操作された非ヒト哺乳動物を前記HLA拘束性抗原と複合体形成された可溶性形態のMHCクラスI分子で免疫化する工程と、
前記非ヒト哺乳動物の抗体産生細胞からmRNA分子を単離する工程と、
前記mRNA分子によってコードされるタンパク質分子をディスプレイするファージディスプレイライブラリーを産生する工程と、
前記ファージディスプレイライブラリーから少なくとも1つのファージを単離する工程であって、前記少なくとも1つのファージが前記HLA拘束性抗原と複合体形成した前記ヒト主要組織適合性複合体(MHC)クラスIと10ナノモル未満の前記結合親和性で特異的に結合することができる前記抗体をディスプレイする工程。 - 前記非ヒト哺乳動物が自己MHCクラスI分子を欠く請求項38記載の方法。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項38記載の方法。
- 前記HLA拘束性抗原が腫瘍HLA拘束性抗原である請求項38記載の方法。
- 前記HLA拘束性抗原がウイルスHLA拘束性抗原である請求項38記載の方法。
- 前記HLA拘束性抗原が自己免疫HLA拘束性抗原である請求項38記載の方法。
- 前記可溶性形態のMHCクラスI分子が、機能的ヒトMHCクラスI重鎖アミノ酸配列に直接または間接的に共有結合した機能的ヒトβ−2ミクログロブリンアミノ酸配列を含む単鎖MHCクラスIポリペプチドである請求項38記載の方法。
- 癌の治療方法であって、前記癌を特徴付ける腫瘍HLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む治療有効量の分子を必要とする被験体に投与する工程と、前記分子が前記抗体に抱合した治療部分をさらに含み、被験体の内因性MHCクラスIと適合する前記MHCクラスI分子が選択されることとを含む、癌の治療方法。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項45記載の方法。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項45記載の方法。
- ウイルス感染の治療方法であって、前記ウイルス感染に起因するウイルスを特徴付けるウイルスHLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む治療有効量の分子を必要とする被験体に投与する工程と、前記分子が抗体に抱合した治療部分をさらに含み、被験体の内因性MHCクラスIと適合する前記MHCクラスI分子が選択されることとを含む、ウイルス感染の治療方法。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項48記載の方法。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項48記載の方法。
- 自己免疫疾患の治療方法であって、自己免疫HLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体を含む治療有効量の分子を必要とする被験体に投与する工程と、前記分子が前記抗体に抱合した治療部分をさらに含み、被験体の内因性MHCクラスIと適合する前記MHCクラスI分子が選択されることとを含む、自己免疫疾患の治療方法。
- 前記MHCクラスI分子は、HLA−A2、HLA−A1、HLA−A3、HLA−A24、HLA−A28、HLA−A31、HLA−A33、HLA−A34、HLA−B7、HLA−B45、およびHLA−Cw8からなる群から選択される請求項51記載の方法。
- 前記治療部分は、細胞傷害性部分、毒性部分、サイトカイン部分、および二重特異性抗体部分からなる群から選択される請求項51記載の方法。
- 免疫毒素の作製方法であって、HLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体をコードする第1のポリヌクレオチドをインフレームで毒素部分をコードする第2のポリヌクレオチドとライゲーションしてライゲーションされたポリヌクレオチドを得る工程と、ライゲーションした前記ポリヌクレオチドを発現系で発現させて前記免疫毒素を得る工程とを含む、免疫毒素の作製方法。
- 前記HLA拘束性抗原は、腫瘍HLA拘束性抗原、ウイルスHLA拘束性抗原、および自己免疫HLA拘束性抗原からなる群から選択される請求項54記載の方法。
- 免疫標識の作製方法であって、HLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体をコードする第1のポリヌクレオチドをインフレームで同定可能な部分をコードする第2のポリヌクレオチドとライゲーションしてライゲーションされたポリヌクレオチドを得る工程と、ライゲーションした前記ポリヌクレオチドを発現系で発現させて前記免疫標識を得る工程とを含む、免疫標識の作製方法。
- 前記HLA拘束性抗原は、腫瘍HLA拘束性抗原、ウイルスHLA拘束性抗原、および自己免疫HLA拘束性抗原からなる群から選択される請求項56記載の方法。
- 免疫標識の作製方法であって、HLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体をコードする第1のポリヌクレオチドをインフレームで同定可能な部分をコードする第2のポリヌクレオチドとライゲーションしてライゲーションされたポリヌクレオチドを得る工程と、ライゲーションした前記ポリヌクレオチドを発現系で発現させて前記免疫標識を得る工程とを含む、免疫標識の作製方法。
- 前記HLA拘束性抗原は、腫瘍HLA拘束性抗原、ウイルスHLA拘束性抗原、および自己免疫HLA拘束性抗原からなる群から選択される請求項54記載の方法。
- 以下の工程を含む、細胞サンプル中のHLA拘束性抗原を提示する抗原提示細胞の存在および/またはレベルの検出方法:
前記サンプルの細胞をHLA拘束性抗原と複合体形成されたヒト主要組織適合性複合体(MHC)クラスIと20ナノモル未満の結合親和性で特異的に結合することができる抗体と相互作用させる工程と、
前記相互作用をモニタリングして前記HLA拘束性抗原を提示する前記抗原提示細胞の存在および/またはレベルを検出する工程。 - 前記HLA拘束性抗原は、腫瘍HLA拘束性抗原、ウイルスHLA拘束性抗原、および自己免疫HLA拘束性抗原からなる群から選択される請求項60記載の方法。
- 配列番号8に記載のポリヌクレオチドを含む単離核酸。
- 配列番号9に記載のアミノ酸配列を含む単離タンパク質。
- 配列番号9に記載のポリペプチドをコードするポリヌクレオチドを含む単離核酸。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/073,301 US6992176B2 (en) | 2002-02-13 | 2002-02-13 | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
PCT/IL2003/000105 WO2003068201A2 (en) | 2002-02-13 | 2003-02-11 | High affinity antibody having a tcr-like specificity and use in detection and treatment |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2005521389A true JP2005521389A (ja) | 2005-07-21 |
JP2005521389A5 JP2005521389A5 (ja) | 2006-02-09 |
JP4272535B2 JP4272535B2 (ja) | 2009-06-03 |
Family
ID=27732335
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003567383A Expired - Fee Related JP4272535B2 (ja) | 2002-02-13 | 2003-02-11 | T細胞受容体様特異性を有し、さらに高親和性の抗体ならびに癌、ウイルス感染、および自己免疫疾患の検出および治療でのその使用 |
Country Status (11)
Country | Link |
---|---|
US (3) | US6992176B2 (ja) |
EP (3) | EP1474120B1 (ja) |
JP (1) | JP4272535B2 (ja) |
AT (1) | ATE446745T1 (ja) |
AU (3) | AU2003208582C1 (ja) |
CA (1) | CA2474782C (ja) |
DE (1) | DE60329823D1 (ja) |
ES (2) | ES2332175T3 (ja) |
HK (1) | HK1068810A1 (ja) |
IL (1) | IL193376A (ja) |
WO (1) | WO2003068201A2 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541937A (ja) * | 2010-08-05 | 2013-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質 |
JP2015504895A (ja) * | 2012-01-13 | 2015-02-16 | エーピーオー‐ティー ビー.ヴイ. | 毒性部分を備える異常細胞拘束性免疫グロブリン |
JPWO2015050259A1 (ja) * | 2013-10-03 | 2017-03-09 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
US11098115B2 (en) | 2011-09-29 | 2021-08-24 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001060391A1 (en) * | 2000-02-15 | 2001-08-23 | Regents Of The University Of California | A universal vaccine and method for treating cancer employing telomerase reverse transcriptase |
US20040191260A1 (en) | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
EP1485075A4 (en) * | 2002-02-20 | 2006-04-26 | Dyax Corp | MHC-PEPTIDE COMPLEX BINDING LIGANDS |
US20040072262A1 (en) * | 2002-10-11 | 2004-04-15 | Montero-Julian Felix A. | Methods and systems for detecting MHC class I binding peptides |
WO2005120166A2 (en) * | 2004-06-09 | 2005-12-22 | Technion Research & Development Foundation Ltd. | Antibodies for selective apoptosis of cells |
AU2005265182B2 (en) * | 2004-06-17 | 2012-06-21 | Mannkind Corporation | Epitope analogs |
WO2007136778A2 (en) * | 2006-05-19 | 2007-11-29 | Teva Pharmaceutical Industries, Ltd. | Fusion proteins, uses thereof and processes for producing same |
US8361473B2 (en) * | 2007-03-29 | 2013-01-29 | Technion Research & Development Foundation Ltd. | Antibodies and their uses for diagnosis and treatment of cytomegalovirus infection and associated diseases |
AU2008234530B2 (en) * | 2007-03-29 | 2013-03-28 | Technion Research & Development Foundation Ltd. | Antibodies, methods and kits for diagnosing and treating melanoma |
US8747855B2 (en) * | 2008-04-09 | 2014-06-10 | Technion Research & Development Foundation Limited | Anti human immunodeficiency antibodies and uses thereof |
EP2297200A1 (en) * | 2008-04-09 | 2011-03-23 | Technion Research & Development Foundation Ltd. | Anti influenza antibodies and uses thereof |
EP2636513B1 (en) * | 2008-04-10 | 2014-08-27 | Stratasys Ltd. | System and method for three dimensional model printing |
PL2119726T5 (pl) | 2008-05-14 | 2018-04-30 | Immatics Biotechnologies Gmbh | Nowe i silne peptydy MHC klasy II pochodzące z surwiwiny i neurokanu |
ES2536465T3 (es) | 2008-10-01 | 2015-05-25 | Immatics Biotechnologies Gmbh | Composición de péptidos tumor-asociados y relacionados con la vacuna contra el cáncer para el tratamiento de glioblastoma (GBM) y otros cánceres |
US20120077696A1 (en) | 2009-03-15 | 2012-03-29 | Technion Research And Development Foundation Ltd. | Soluble hla complexes for use in disease diagnosis |
SG177025A1 (en) * | 2010-06-21 | 2012-01-30 | Agency Science Tech & Res | Hepatitis b virus specific antibody and uses thereof |
WO2012129520A1 (en) | 2011-03-24 | 2012-09-27 | Texas Tech University System | Tcr mimic antibodies as vascular targeting tools |
AU2012236068A1 (en) | 2011-04-01 | 2013-10-17 | Eureka Therapeutics, Inc. | T cell receptor-like antibodies specific for a WT1 peptide presented by HLA-A2 |
UA114108C2 (uk) | 2012-07-10 | 2017-04-25 | Борд Оф Ріджентс, Дзе Юніверсіті Оф Техас Сістем | Моноклональне антитіло для застосування в діагностиці і терапії злоякісних пухлин і аутоімунного захворювання |
TWI777197B (zh) | 2013-08-05 | 2022-09-11 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類,細胞及其用於治療多種腫瘤的用途,其製造方法及包含其等之醫藥組成物(六) |
GB201319446D0 (en) | 2013-11-04 | 2013-12-18 | Immatics Biotechnologies Gmbh | Personalized immunotherapy against several neuronal and brain tumors |
GB201408255D0 (en) | 2014-05-09 | 2014-06-25 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumours of the blood, such as acute myeloid leukemia (AML) |
GB201411037D0 (en) | 2014-06-20 | 2014-08-06 | Immatics Biotechnologies Gmbh | Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemai (CLL) |
US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
BR112017005245A2 (pt) | 2014-09-19 | 2017-12-12 | Regeneron Pharma | animal não humano geneticamente modificado, métodos para produzir célula t, hibridoma de célula t, um ácido nucleico, um anticorpo específico, uma célula humana, um animal não humano geneticamente modificado e para induzir uma resposta imunológica, célula, hibridoma de célula t, ácido nucleico, anticorpo específico, receptor de antígeno quimérico, embrião não humano, locus de um receptor de antígeno quimérico, e, composição de ácidos nucleicos. |
GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
MD3388075T2 (ro) | 2015-03-27 | 2023-10-31 | Immatics Biotechnologies Gmbh | Noi peptide și combinații de peptide pentru utilizare în imunoterapia împotriva unor diverse tumori (SEQ ID 25 - MXRA5-003) |
GB201505585D0 (en) | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
MX2017012352A (es) | 2015-04-03 | 2018-01-26 | Eureka Therapeutics Inc | Construccion dirigida a complejos de peptido de alfa-fetoproteina/complejo principal de histocompatibilidad (afp/cph) y usos de los mismos. |
GB201507030D0 (en) | 2015-04-24 | 2015-06-10 | Immatics Biotechnologies Gmbh | Immunotherapy against lung cancers, in particular NSCLC |
WO2016174652A1 (en) | 2015-04-30 | 2016-11-03 | Technion Research & Development Foundation Limited | Chimeric antigen receptors and methods of their use |
GB201507719D0 (en) | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
NL2014935B1 (en) | 2015-06-08 | 2017-02-03 | Applied Immune Tech Ltd | T cell receptor like antibodies having fine specificity. |
GB201511546D0 (en) | 2015-07-01 | 2015-08-12 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers |
MA42294B1 (fr) | 2015-07-01 | 2020-11-30 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
MA51531A (fr) | 2015-07-06 | 2020-11-11 | Immatics Biotechnologies Gmbh | Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers |
WO2017009852A1 (en) | 2015-07-16 | 2017-01-19 | Yeda Research And Development Co. Ltd. | Use of anti third party central memory t cells |
GB201513921D0 (en) | 2015-08-05 | 2015-09-23 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers |
CN115927191A (zh) | 2015-10-23 | 2023-04-07 | 优瑞科生物技术公司 | 抗体/t细胞受体嵌合构建体及其用途 |
GB201522667D0 (en) | 2015-12-22 | 2016-02-03 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against breast cancer and other cancers |
AU2016381964B2 (en) | 2015-12-30 | 2024-02-15 | Kodiak Sciences Inc. | Antibodies and conjugates thereof |
GB201602918D0 (en) | 2016-02-19 | 2016-04-06 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against NHL and other cancers |
CN116375797A (zh) | 2016-03-01 | 2023-07-04 | 伊玛提克斯生物技术有限公司 | 用于膀胱癌和其他癌症免疫治疗的肽、肽组合物和细胞类药物 |
EP4219524A3 (en) | 2016-04-06 | 2023-10-18 | immatics biotechnologies GmbH | Novel peptides and combination of peptides for use in immunotherapy against aml and other cancers |
MA45491A (fr) | 2016-06-27 | 2019-05-01 | Juno Therapeutics Inc | Épitopes à restriction cmh-e, molécules de liaison et procédés et utilisations associés |
CA3028002A1 (en) | 2016-06-27 | 2018-01-04 | Juno Therapeutics, Inc. | Method of identifying peptide epitopes, molecules that bind such epitopes and related uses |
TWI796299B (zh) | 2016-08-26 | 2023-03-21 | 德商英麥提克生物技術股份有限公司 | 用於頭頸鱗狀細胞癌和其他癌症免疫治療的新型肽和支架 |
WO2018057967A2 (en) * | 2016-09-23 | 2018-03-29 | Eureka Therapeutics, Inc. | Constructs targeting hiv peptide/mhc complexes and uses thereof |
EP3548083A1 (en) | 2016-12-03 | 2019-10-09 | Juno Therapeutics, Inc. | Methods for modulation of car-t cells |
MA46963A (fr) | 2016-12-03 | 2019-10-09 | Juno Therapeutics Inc | Méthodes pour déterminer le dosage de céllules car-t |
CA3045338A1 (en) | 2016-12-05 | 2018-06-14 | Juno Therapeutics, Inc. | Production of engineered cells for adoptive cell therapy |
CN107686522A (zh) * | 2016-12-28 | 2018-02-13 | 天津天锐生物科技有限公司 | 一种识别hla‑a2/sllmwitqc的单域抗体 |
WO2018132518A1 (en) | 2017-01-10 | 2018-07-19 | Juno Therapeutics, Inc. | Epigenetic analysis of cell therapy and related methods |
WO2018134824A1 (en) | 2017-01-18 | 2018-07-26 | Yeda Research And Development Co. Ltd. | Genetically modified veto cells and use of same in immunotherapy |
CN110418802A (zh) | 2017-01-20 | 2019-11-05 | 朱诺治疗学有限公司 | 细胞表面缀合物及相关的细胞组合物和方法 |
MA47367B1 (fr) | 2017-01-27 | 2023-06-28 | Immatics Biotechnologies Gmbh | Nouveaux peptides et combinaison de peptides à utiliser en immunothérapie contre le cancer de l'ovaire et d'autres cancers |
CN110461335A (zh) | 2017-02-17 | 2019-11-15 | 弗雷德哈钦森癌症研究中心 | 用于治疗bcma相关癌症和自身免疫性失调的联合疗法 |
US20200191774A1 (en) | 2017-02-27 | 2020-06-18 | Juno Therapeutics, Inc. | Compositions, articles of manufacture and methods related to dosing in cell therapy |
MX2019012017A (es) | 2017-04-07 | 2020-02-12 | Juno Therapeutics Inc | Celulas modificadas que expresan antigeno de membrana especifico de prostata (psma) o una forma modificada del mismo y metodos relacionados. |
WO2018189148A1 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination thereof for use in the immunotherapy against cancers |
WO2018189152A2 (en) | 2017-04-10 | 2018-10-18 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers |
CR20210159A (es) | 2017-04-10 | 2021-05-21 | Immatics Biotechnologies Gmbh | Péptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cáncer (divisional de solicitud 2019-0508) |
MX2019012189A (es) | 2017-04-14 | 2020-12-10 | Juno Therapeutics Inc | Metodos para valorar la glucosilacion de la superficie celular. |
AU2018258046A1 (en) | 2017-04-26 | 2019-12-12 | Eureka Therapeutics, Inc. | Cells expressing chimeric activating receptors and chimeric stimulating receptors and uses thereof |
JP7379164B2 (ja) | 2017-06-02 | 2023-11-14 | ジュノー セラピューティクス インコーポレイテッド | 細胞療法に関連する毒性に関する製造物品および方法 |
US11485785B2 (en) | 2017-06-14 | 2022-11-01 | Adicet Bio, Inc. | Antibodies capable of binding HLA-A2/TyrD in an HLA restricted manner and uses thereof |
WO2019007974A1 (en) | 2017-07-07 | 2019-01-10 | Immatics Biotechnologies Gmbh | NOVEL PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF LUNG CANCER, INCLUDING NSCLC, CPPC AND OTHER CANCERS |
SG11201913302SA (en) | 2017-07-07 | 2020-01-30 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against lung cancer, including nsclc, sclc and other cancers |
WO2019027850A1 (en) | 2017-07-29 | 2019-02-07 | Juno Therapeutics, Inc. | CELL EXPANSION REAGENTS EXPRESSING RECOMBINANT RECEPTORS |
WO2019028266A1 (en) | 2017-08-02 | 2019-02-07 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | HEPATITIS B NANOPARTICLE VACCINE FOR INFLUENZA VIRUS |
US20200239910A1 (en) | 2017-08-09 | 2020-07-30 | Juno Therapeutics, Inc. | Methods and compositions for preparing genetically engineered cells |
JP7275104B2 (ja) | 2017-08-09 | 2023-05-17 | ジュノー セラピューティクス インコーポレイテッド | 遺伝子操作された細胞の組成物および関連組成物を産生するための方法 |
WO2019051335A1 (en) | 2017-09-07 | 2019-03-14 | Juno Therapeutics, Inc. | METHODS OF IDENTIFYING CELLULAR CHARACTERISTICS RELATED TO RESPONSES ASSOCIATED WITH CELL THERAPY |
US11851679B2 (en) | 2017-11-01 | 2023-12-26 | Juno Therapeutics, Inc. | Method of assessing activity of recombinant antigen receptors |
EP3706754A1 (en) | 2017-11-06 | 2020-09-16 | Juno Therapeutics, Inc. | Combination of a cell therapy and a gamma secretase inhibitor |
EP3716980A1 (en) | 2017-12-01 | 2020-10-07 | Juno Therapeutics, Inc. | Methods for dosing and for modulation of genetically engineered cells |
US20210207080A1 (en) | 2017-12-08 | 2021-07-08 | Juno Therapeutics, Inc. | Serum-free media formulation for culturing cells and methods of use thereof |
WO2019113559A2 (en) | 2017-12-08 | 2019-06-13 | Juno Therapeutics, Inc. | Phenotypic markers for cell therapy and related methods |
SG11202005272SA (en) | 2017-12-08 | 2020-07-29 | Juno Therapeutics Inc | Process for producing a composition of engineered t cells |
EP3746117A1 (en) | 2018-01-31 | 2020-12-09 | Celgene Corporation | Combination therapy using adoptive cell therapy and checkpoint inhibitor |
DE102018107224A1 (de) | 2018-02-21 | 2019-08-22 | Immatics Biotechnologies Gmbh | Peptide und Kombinationen von Peptiden nicht-kanonischen Ursprungs zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
MA52656A (fr) | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées |
TW202016131A (zh) | 2018-05-16 | 2020-05-01 | 德商英麥提克生物技術股份有限公司 | 用於抗癌免疫治療的肽 |
US10925947B2 (en) | 2018-06-29 | 2021-02-23 | Immatics Biotechnologies Gmbh | A*03 restricted peptides for use in immunotherapy against cancers and related methods |
TW202019955A (zh) | 2018-07-31 | 2020-06-01 | 德商英麥提克生物技術股份有限公司 | B*07 限制肽和肽組合的抗癌免疫治療和相關方法 |
KR20210057730A (ko) | 2018-08-09 | 2021-05-21 | 주노 쎄러퓨티크스 인코퍼레이티드 | 조작 세포 및 이의 조성물 생성 방법 |
EA202190469A1 (ru) | 2018-08-09 | 2021-06-28 | Джуно Терапьютикс, Инк. | Способы оценки интегрированных нуклеиновых кислот |
BR112021004261A2 (pt) | 2018-09-11 | 2021-05-25 | Juno Therapeutics Inc | métodos para análise por espectrometria de massas de composições de células geneticamente modificadas |
US11945850B2 (en) | 2018-09-17 | 2024-04-02 | Immatics Biotechnologies Gmbh | B*44 restricted peptides for use in immunotherapy against cancers and related methods |
TW202024121A (zh) | 2018-09-18 | 2020-07-01 | 德商英麥提克生物技術股份有限公司 | A*01 限制肽和肽組合物在抗癌免疫治療中的用途和相關方法 |
SG11202104355SA (en) | 2018-10-31 | 2021-05-28 | Juno Therapeutics Gmbh | Methods for selection and stimulation of cells and apparatus for same |
KR20210117260A (ko) | 2018-11-30 | 2021-09-28 | 주노 쎄러퓨티크스 인코퍼레이티드 | 입양 세포 요법을 사용한 치료방법 |
TW202039535A (zh) | 2018-12-18 | 2020-11-01 | 德商英麥提克生物技術股份有限公司 | B*08限制肽和肽組合物抗癌免疫治療和相關方法 |
BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
KR20220034782A (ko) | 2019-06-12 | 2022-03-18 | 주노 쎄러퓨티크스 인코퍼레이티드 | 세포 매개 세포 독성 요법 및 친생존 bcl2 패밀리 단백질 억제제의 병용 요법 |
EP4017527A1 (en) | 2019-08-22 | 2022-06-29 | Juno Therapeutics, Inc. | Combination therapy of a t cell therapy and an enhancer of zeste homolog 2 (ezh2) inhibitor and related methods |
EP4021493A1 (en) | 2019-08-29 | 2022-07-06 | Eberhard Karls Universität Tübingen, Medizinische Fakultät | T cell epitopes of hcmv and uses of thereof |
JP2022553640A (ja) | 2019-10-10 | 2022-12-26 | コディアック サイエンシーズ インコーポレイテッド | 眼障害を処置する方法 |
KR20220146480A (ko) | 2020-01-28 | 2022-11-01 | 주노 쎄러퓨티크스 인코퍼레이티드 | T 세포 형질도입 방법 |
US20230178239A1 (en) | 2020-05-13 | 2023-06-08 | Juno Therapeutics, Inc. | Methods of identifying features associated with clinical response and uses thereof |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
DE102020125465A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch nicht-HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
DE102020125457A1 (de) | 2020-09-29 | 2022-03-31 | Immatics Biotechnologies Gmbh | Amidierte Peptide und ihre deamidierten Gegenstücke, die durch HLA-A*02-Moleküle präsentiert werden, zur Verwendung in der Immuntherapie gegen verschiedene Krebsarten |
TW202229312A (zh) | 2020-09-29 | 2022-08-01 | 德商英麥提克生物技術股份有限公司 | 由非hla-a*02顯露以用於不同類型癌症之免疫治療的醯胺化肽及其脫醯胺化對應物 |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022133030A1 (en) | 2020-12-16 | 2022-06-23 | Juno Therapeutics, Inc. | Combination therapy of a cell therapy and a bcl2 inhibitor |
TW202241925A (zh) | 2021-01-15 | 2022-11-01 | 德商英麥提克生物技術股份有限公司 | 用於不同類型癌症免疫治療的hla展示肽 |
WO2022187050A1 (en) * | 2021-03-01 | 2022-09-09 | BioLegend, Inc. | Anti-cd117 agents and compositions and methods for making and using the same |
AU2022244229A1 (en) | 2021-03-22 | 2023-09-14 | Juno Therapeutics, Inc. | Method to assess potency of viral vector particles |
AU2022241654A1 (en) | 2021-03-22 | 2023-09-28 | Juno Therapeutics, Inc. | Methods of determining potency of a therapeutic cell composition |
BR112023019847A2 (pt) | 2021-03-29 | 2023-11-07 | Juno Therapeutics Inc | Métodos para dosagem e tratamento com uma combinação de uma terapia com inibidor de ponto de verificação e uma terapia com célula t car |
KR20240054423A (ko) | 2021-08-10 | 2024-04-25 | 가미다-셀 리미티드 | 조작된 nk 세포, 이의 생산방법 및 용도 |
WO2023147515A1 (en) | 2022-01-28 | 2023-08-03 | Juno Therapeutics, Inc. | Methods of manufacturing cellular compositions |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04505401A (ja) * | 1990-02-14 | 1992-09-24 | アンステイテユ・ナシオナル・ドウ・ラ・サンテ・エ・ドウ・ラ・ルシエルシユ・メデイカル | 主要組織適合抗原に会合したペプチドを認識するモノクローナル抗体 |
JPH11510375A (ja) * | 1995-06-30 | 1999-09-14 | コベンハブンズ ユニバーサイテッド | ペプチド−mhc複合体を指向するファージディスプレイライブラリーからの組換え抗体 |
WO2001072768A2 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
WO2001096401A1 (fr) * | 2000-06-14 | 2001-12-20 | Medical & Biological Laboratories Co., Ltd. | Procede de construction d'un anticorps scfv fusionne a une proteine fluorescente |
JP2005533486A (ja) * | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Mhc−ペプチド複合体結合リガンド |
Family Cites Families (61)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL154600B (nl) * | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
NL154598B (nl) * | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
NL154599B (nl) * | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
US3901654A (en) * | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
US3853987A (en) * | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
US3867517A (en) * | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
NL171930C (nl) * | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
US3850578A (en) * | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
US6416738B1 (en) * | 1973-12-07 | 2002-07-09 | Neorx Corporation | Pretargeting methods and compounds |
US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
US4736866A (en) | 1984-06-22 | 1988-04-12 | President And Fellows Of Harvard College | Transgenic non-human mammals |
US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
DE3854823T2 (de) | 1987-05-01 | 1996-05-23 | Stratagene Inc | Mutagenesetest durch Verwendung von nicht menschlichen Lebewesen, die Test-DNS-Sequenzen enthalten |
US5591829A (en) * | 1987-05-29 | 1997-01-07 | Matsushita; Shuzo | Antibodies modified with toxic substance |
US5175385A (en) | 1987-09-03 | 1992-12-29 | Ohio University/Edison Animal Biotechnolgy Center | Virus-resistant transgenic mice |
US5221778A (en) | 1988-08-24 | 1993-06-22 | Yale University | Multiplex gene regulation |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
US5175383A (en) | 1989-02-17 | 1992-12-29 | President And Fellows Of Harvard College | Animal model for benign prostatic disease |
US6291160B1 (en) * | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for producing polymers having a preselected activity |
US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
DE69133372T2 (de) | 1990-06-15 | 2005-02-24 | Scios Inc., Sunnyvale | Transgenes, nicht-menschliches säugetier das die amyloidbildende pathologie der alzheimerschen krankheit zeigt |
US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5288846A (en) | 1990-10-19 | 1994-02-22 | The General Hospital Corporation | Cell specific gene regulators |
US5298422A (en) | 1991-11-06 | 1994-03-29 | Baylor College Of Medicine | Myogenic vector systems |
PT620849E (pt) | 1992-01-07 | 2003-11-28 | Elan Pharm Inc | Modelos animais transgenicos para a doenca de alzheimer |
US5360735A (en) | 1992-01-08 | 1994-11-01 | Synaptic Pharmaceutical Corporation | DNA encoding a human 5-HT1F receptor, vectors, and host cells |
US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
EP0663952A4 (en) | 1992-09-11 | 1997-06-11 | Univ California | TRANSGENIC NON-HUMAN ANIMALS WITH TARGETED INTERRUPTED TRANSDUCTION GENES IN LYMPHOCYTES. |
US20030129191A1 (en) * | 1992-12-23 | 2003-07-10 | Neorx Corporation | Pretargeting methods and compounds |
WO1994023049A2 (en) | 1993-04-02 | 1994-10-13 | The Johns Hopkins University | The introduction and expression of large genomic sequences in transgenic animals |
US6664107B1 (en) | 1993-05-26 | 2003-12-16 | Ontario Cancer Institute, University Health Network | CD45 disrupted nucleic acid |
US5695928A (en) * | 1993-12-10 | 1997-12-09 | Novartis Corporation | Rapid immunoassay for detection of antibodies or antigens incorporating simultaneous sample extraction and immunogenic reaction |
JPH10505481A (ja) * | 1994-04-22 | 1998-06-02 | アメリカ合衆国 | メラノーマ抗原 |
GB9415492D0 (en) * | 1994-08-01 | 1994-09-21 | Celltech Ltd | Biological products |
US6232445B1 (en) * | 1997-10-29 | 2001-05-15 | Sunol Molecular Corporation | Soluble MHC complexes and methods of use thereof |
BR0010017A (pt) * | 1999-04-28 | 2002-06-11 | Univ Texas | Composições e processos para o tratamento de câncer por inibição seletiva de vegf |
AUPQ115499A0 (en) | 1999-06-24 | 1999-07-15 | Colocare Holdings Pty Limited | Colostomy pump device |
US6680209B1 (en) * | 1999-12-06 | 2004-01-20 | Biosite, Incorporated | Human antibodies as diagnostic reagents |
US20040191260A1 (en) * | 2003-03-26 | 2004-09-30 | Technion Research & Development Foundation Ltd. | Compositions capable of specifically binding particular human antigen presenting molecule/pathogen-derived antigen complexes and uses thereof |
EP1178116A1 (en) * | 2000-08-03 | 2002-02-06 | Hybrigenics S.A. | Sid nucleic acids and polypeptides selected from a pathogenic strain of hepatitis C virus and applications thereof |
US6992176B2 (en) * | 2002-02-13 | 2006-01-31 | Technion Research & Development Foundation Ltd. | Antibody having a T-cell receptor-like specificity, yet higher affinity, and the use of same in the detection and treatment of cancer, viral infection and autoimmune disease |
US7632866B2 (en) * | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
-
2002
- 2002-02-13 US US10/073,301 patent/US6992176B2/en not_active Expired - Fee Related
-
2003
- 2003-02-11 DE DE60329823T patent/DE60329823D1/de not_active Expired - Lifetime
- 2003-02-11 EP EP03706876A patent/EP1474120B1/en not_active Expired - Lifetime
- 2003-02-11 EP EP10011766.2A patent/EP2329814B1/en not_active Expired - Lifetime
- 2003-02-11 WO PCT/IL2003/000105 patent/WO2003068201A2/en active Application Filing
- 2003-02-11 ES ES03706876T patent/ES2332175T3/es not_active Expired - Lifetime
- 2003-02-11 CA CA2474782A patent/CA2474782C/en not_active Expired - Lifetime
- 2003-02-11 JP JP2003567383A patent/JP4272535B2/ja not_active Expired - Fee Related
- 2003-02-11 ES ES10011766T patent/ES2425539T3/es not_active Expired - Lifetime
- 2003-02-11 EP EP09001632A patent/EP2072045B1/en not_active Revoked
- 2003-02-11 AT AT03706876T patent/ATE446745T1/de not_active IP Right Cessation
- 2003-02-11 AU AU2003208582A patent/AU2003208582C1/en not_active Ceased
-
2005
- 2005-02-23 HK HK05101505.1A patent/HK1068810A1/xx not_active IP Right Cessation
- 2005-08-15 US US11/203,137 patent/US20050287141A1/en not_active Abandoned
-
2008
- 2008-03-06 AU AU2008201062A patent/AU2008201062B2/en not_active Ceased
- 2008-08-11 IL IL193376A patent/IL193376A/en active IP Right Grant
-
2010
- 2010-08-26 AU AU2010214669A patent/AU2010214669B2/en not_active Ceased
-
2011
- 2011-06-19 US US13/163,701 patent/US20110318369A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04505401A (ja) * | 1990-02-14 | 1992-09-24 | アンステイテユ・ナシオナル・ドウ・ラ・サンテ・エ・ドウ・ラ・ルシエルシユ・メデイカル | 主要組織適合抗原に会合したペプチドを認識するモノクローナル抗体 |
JPH11510375A (ja) * | 1995-06-30 | 1999-09-14 | コベンハブンズ ユニバーサイテッド | ペプチド−mhc複合体を指向するファージディスプレイライブラリーからの組換え抗体 |
WO2001072768A2 (en) * | 2000-03-27 | 2001-10-04 | Technion Research And Development Foundation Ltd. | Single chain class i major histo-compatibility complexes, constructs encoding same and methods of generating same |
WO2001096401A1 (fr) * | 2000-06-14 | 2001-12-20 | Medical & Biological Laboratories Co., Ltd. | Procede de construction d'un anticorps scfv fusionne a une proteine fluorescente |
JP2005533486A (ja) * | 2002-02-20 | 2005-11-10 | ダイアックス、コープ | Mhc−ペプチド複合体結合リガンド |
Non-Patent Citations (8)
Title |
---|
CANCER RES.,VOL.62,NO.20(2002.OCT.)P.5835-5844, JPN6008029241, ISSN: 0001241133 * |
EUR.J.IMMUNOL.,VOL.30,NO.12(2000)P.3522-3532, JPN6008029237, ISSN: 0001065736 * |
IMMUNOTECHNOLOGY,VOL.4,NO.3-4(1999)P.273-238, JPN6008029244, ISSN: 0001241136 * |
J.IMMUNOL.,VOL.167,NO.1(2001)P.270-276, JPN6008029242, ISSN: 0001241134 * |
J.IMMUNOL.,VOL.169,NO.8(2002.OCT.)P.4399-4407, JPN6008029239, ISSN: 0001241131 * |
PROC.NATL.ACAD.SCI.USA.,VOL.94,NO.9(1997)P.4631-4636, JPN6008029238, ISSN: 0001065737 * |
PROC.NATL.ACAD.SCI.USA.,VOL.97,NO.14(2000)P.7969-7974, JPN6008029243, ISSN: 0001241135 * |
PROC.NATL.ACAD.SCI.USA.,VOL.99,NO.14(2002.JUL.)P.9421-6, JPN6008029240, ISSN: 0001241132 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013541937A (ja) * | 2010-08-05 | 2013-11-21 | エフ.ホフマン−ラ ロシュ アーゲー | 抗mhc抗体−抗ウイルス性サイトカイン融合タンパク質 |
US11098115B2 (en) | 2011-09-29 | 2021-08-24 | Apo-T B.V. | Multi-specific binding molecules targeting aberrant cells |
JP2015504895A (ja) * | 2012-01-13 | 2015-02-16 | エーピーオー‐ティー ビー.ヴイ. | 毒性部分を備える異常細胞拘束性免疫グロブリン |
JP2018083814A (ja) * | 2012-01-13 | 2018-05-31 | エーピーオー‐ティー ビー.ヴイ. | 毒性部分を備える異常細胞拘束性免疫グロブリン |
US10946104B2 (en) | 2012-01-13 | 2021-03-16 | Apo-Tb.V. | Aberrant cell-restricted immunoglobulins provided with a toxic moiety |
JPWO2015050259A1 (ja) * | 2013-10-03 | 2017-03-09 | 大日本住友製薬株式会社 | 腫瘍抗原ペプチド |
Also Published As
Publication number | Publication date |
---|---|
EP2072045A2 (en) | 2009-06-24 |
AU2003208582A1 (en) | 2003-09-04 |
AU2003208582B2 (en) | 2007-12-06 |
DE60329823D1 (de) | 2009-12-10 |
ES2332175T3 (es) | 2010-01-28 |
IL193376A0 (en) | 2009-02-11 |
AU2008201062A1 (en) | 2008-04-03 |
WO2003068201A3 (en) | 2003-12-04 |
ES2425539T3 (es) | 2013-10-16 |
EP1474120A4 (en) | 2005-10-12 |
JP4272535B2 (ja) | 2009-06-03 |
AU2010214669A1 (en) | 2010-09-16 |
EP1474120B1 (en) | 2009-10-28 |
WO2003068201A2 (en) | 2003-08-21 |
US20050287141A1 (en) | 2005-12-29 |
EP2072045A3 (en) | 2010-09-22 |
EP2072045B1 (en) | 2012-08-15 |
EP1474120A2 (en) | 2004-11-10 |
CA2474782A1 (en) | 2003-08-21 |
AU2010214669B2 (en) | 2012-01-12 |
ATE446745T1 (de) | 2009-11-15 |
AU2003208582C1 (en) | 2008-08-07 |
AU2008201062B2 (en) | 2010-10-28 |
US6992176B2 (en) | 2006-01-31 |
HK1068810A1 (en) | 2005-05-06 |
US20050255101A1 (en) | 2005-11-17 |
IL193376A (en) | 2013-11-28 |
CA2474782C (en) | 2017-05-30 |
EP2329814A1 (en) | 2011-06-08 |
US20110318369A1 (en) | 2011-12-29 |
EP2329814B1 (en) | 2013-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4272535B2 (ja) | T細胞受容体様特異性を有し、さらに高親和性の抗体ならびに癌、ウイルス感染、および自己免疫疾患の検出および治療でのその使用 | |
JP5148804B2 (ja) | 癌の治療に特に有用な免疫擬装の方法及び薬学的組成物 | |
US20100158927A1 (en) | Antibodies, methods and kits for diagnosing and treating melanoma | |
WO2016154047A2 (en) | Monoclonal antigen-binding proteins to intracellular oncogene products | |
JP2016502515A (ja) | 新規抗原結合タンパク質および癌の治療のためのアドレッシング産物(addressingproduct)としてのそれらの使用 | |
KR20220160584A (ko) | 다중-특이적 항체를 통한 형질전환 성장 인자 베타 슈퍼패밀리 신호전달의 선택적 조정 | |
US8449889B2 (en) | Immuno-molecules containing viral proteins, compositions thereof and methods of using | |
AU2008243241B2 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
US20170198046A1 (en) | Compositions capable of specifically binding particular human antigen presenting molecule/ antigen complexes and uses thereof | |
ZA200309308B (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer | |
AU2002304279A1 (en) | Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051212 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20051212 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080613 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080813 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080820 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081009 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20081107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090115 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090203 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090227 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120306 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120306 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130306 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130306 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140306 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
LAPS | Cancellation because of no payment of annual fees |